Search results: (10000)
News The Immune System in the Pathophysiology of ITP
From the perspective of the pathophysiology of immune thrombocytopenia (ITP), it appears that the etiology of this disease is very complex and involves both antibody and cellular immunity.
News Quality of Life of Hemophiliacs and Ways to Improve It
Determining the quality of life (QoL) also reflects the morbidity associated with the disease, in this case, hemophilia. In the study presented below, the authors focused on determining QoL in relation to socioeconomic and other characteristics.
News Two Is Not Enough: Efficacy of Alemtuzumab in Subsequent Cycles
The goal of the recent pooled analysis of the CARE-MS and TOPAZ study results published in the journal Multiple Sclerosis was to evaluate the efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS) who received alemtuzumab in additional cycles beyond the first 2 cycles.
News Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
The standard treatment for hemophilia A is the prophylactic administration of coagulation factor VIII (FVIII) concentrate. Recently, some hemophiliacs have also been switched to prophylaxis with so-called non-factor therapy, specifically emicizumab. A recently published report from the USA shows a comparison of these two modalities in real clinical practice.
News Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?
The results of the TOWER study extension were published this August in the prestigious journal Multiple Sclerosis and Related Disorders. So, how did teriflunomide fare in this recent evaluation for the treatment of relapsing-remitting multiple sclerosis?
News Position of Parenteral Therapy in Patients with Severe COVID-19 Disease
Patients with severe COVID-19 disease are at risk of developing acute respiratory insufficiency requiring non-invasive or invasive pulmonary ventilation. Intensive care therapy is associated with a high risk of severe malnutrition. According to current recommendations by the European Society for Clinical Nutrition and Metabolism, parenteral therapy plays an important role in the nutrition of patients.
News Impact of Adequate Protein Intake on Morbidity and Mortality in Critically Ill Patients
The following text provides a summary of findings from clinical studies in the field of nutritional therapy for critically ill patients and its impact on protein metabolism and patient outcomes.
News Dupilumab in the Treatment of Severe Asthma in Real-World Practice
A freshly published French study is the first to confirm the results of clinical trials with dupilumab in patients with severe asthma in real-world practice.
News Inflammation, Polyunsaturated Fatty Acids and Their Significance in the Development and Treatment of Depression
Depression is currently a highly discussed disease with a prevalence that is likely to rise. Therefore, scientists are focusing on potential causes and new treatment modalities. It has been shown that inflammation, which can be influenced by polyunsaturated fatty acids, likely plays a role in the development of the disease. Inflammation is also a possible explanation for the frequent coexistence of depression and metabolic syndrome.
News The Importance of Adequate Protein Intake in Critical Patients – Analysis of Data from an International Study
Adequate protein intake is a necessary part of care for critically ill patients and mitigates catabolic reactions associated with severe illness or injury. The benefits of proper determination and adherence to protein intake, however, have not been sufficiently assessed in detail. Therefore, this topic was the focus of a work analyzing data from an international observational multicenter study published in the Journal of Parenteral and Enteral Nutrition.
News Autonomic Dysfunction in Patients with Transthyretin Amyloidosis
Autonomic nervous system disorders are a common complication of transthyretin amyloidosis. Their frequency, nature, and impact on patients' quality of life were examined in the longitudinal THAOS study.
News HPD 2024: Czech data from real-world practice confirm that mucolytic treatment can reduce COPD exacerbations, even in the future
Chronic obstructive pulmonary disease (COPD) is a global issue. Does it create the same burden everywhere? How does it contribute to premature deaths? How do women cope with COPD, and what significant problem does it pose for them? What factors contribute to it not being considered solely a smoker's disease? Why is it appropriate to add mucoactive agents when trying to eliminate COPD exacerbations? What emerged from early COPD screening conducted in the Czech Republic, and what do Czech real-world data show regarding the effectiveness of erdosteine in exacerbations? And what should be included in the proper diagnosis and treatment of this disease? All these topics were covered in a lecture by the head of the Pulmonary Clinic of the Medical Faculty of Charles University and University Hospital Hradec Králové, Associate Professor Vladimír Koblížek, M.D., Ph.D., during the XXVIII Hradec Pneumology Days held from April 24-26, 2024.
News Modern Techniques and MRI Markers in Multiple Sclerosis Imaging or How to Increase Specificity and Sensitivity of Examinations
MRI is a key component in the diagnosis of multiple sclerosis (MS). However, despite significant progress in imaging methods, specificity is still not optimal. The current trend is to refine and clearly define MRI criteria for diagnosing multiple sclerosis and distinguishing it from MS-mimicking white matter lesions.
News Overview of the Efficacy of the Fixed Combination Aclidinium-Bromide/Formoterol-Fumarate in the Maintenance Treatment of COPD
Fixed combination inhalation medications have become the cornerstone of pharmacotherapy for moderate to severe chronic obstructive pulmonary disease (COPD). American authors have published an overview of study results evaluating the efficacy and safety of one of the newest fixed combinations of LABA/LAMA, aclidinium-bromide and formoterol-fumarate (AB/FF), in the maintenance treatment of COPD compared to placebo or other medications. These clinical studies investigated the extent to which regular use of this fixed combination alleviates COPD symptoms, improves lung function, reduces the incidence of exacerbations, and increases exercise tolerance.
News Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction
Ivabradine and sacubitril/valsartan are used in the second line of therapy for heart failure with reduced ejection fraction (HFrEF). The aim of the study presented below was to evaluate the synergistic effect of these modern medications.
News Efficacy of Ceftazidime/Avibactam in the Treatment of Infections Caused by Carbapenemase-Producing Enterobacteria
Infections caused by carbapenemase-producing enterobacteria are associated with high mortality, and their incidence continues to rise. The study presented below investigated the efficacy of therapy with the combination of ceftazidime/avibactam (a third-generation cephalosporin and a beta-lactamase inhibitor) in treating these infections compared to the 'best available antibiotic therapy' (BAT).
News Current Findings on Progressive Fibrosis in Interstitial Lung Disease
Leading pulmonologists around the world recently published the first of a series of three review articles on interstitial lung disease in The Lancet Respiratory Medicine journal. This article focuses on histopathology and the relationship of this disease with lung fibrosis. It also addresses the question of whether progressive lung tissue fibrosis pertains only to usual interstitial pneumonia.
News What Response to the COVID-19 Vaccine Can Be Expected in Patients After Stem Cell Transplantation?
During the recent virtual congress of the European Society for Blood and Marrow Transplantation (EBMT 2022), a study by Saudi experts was presented that explored the response to vaccination against SARS-CoV-2, the causative agent of COVID-19, in patients who had undergone stem cell transplantation (SCT).
News Stabilization of Transthyretin and Long-term Survival of Patients with Cardiac Amyloidosis
Tafamidis is used in the therapy of transthyretin amyloid cardiomyopathy (ATTR-CM), which has proven its benefit in the ATTR-ACT clinical study. The results of its open-label extension study show that early diagnosis and prompt initiation of therapy are crucial.
News Efficacy and Safety of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction
Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetics and non-diabetics. The aim of the EMPEROR-Preserved clinical trial was to supplement data on the efficacy and safety of empagliflozin in a population of patients with heart failure with preserved ejection fraction (HFpEF; EF LK > 40%).
News Can Antihypertensives Reduce the Risk of Dementia? The Answer Suggests the Angiotensin Hypothesis and a Post-Hoc Analysis of an Observational Study
The use of antihypertensives that do not reduce angiotensin II levels, such as angiotensin receptor blockers (ARBs, i.e., sartans) and calcium channel blockers (CCBs), has been associated with a lower risk of dementia in studies. In the research cited below, the authors aimed to determine whether this effect persists longer than the follow-up period in previous studies.